A novel mimetic antigen eliciting protective antibody to Neisseria meningitidis.
Molecular mimetic Ags are of considerable interest as vaccine candidates. Yet there are few examples of mimetic Ags that elicit protective Ab against a pathogen, and the functional activity of anti-mimetic Abs has not been studied in detail. As part of the Neisseria meningitidis serogroup B genome sequencing project, a large number of novel proteins were identified. Herein, we provide evidence that genome-derived Ag 33 (GNA33), a lipoprotein with homology to Escherichia coli murein transglycosylase, elicits protective Ab to meningococci as a result of mimicking an epitope on loop 4 of porin A (PorA) in strains with serosubtype P1.2. Epitope mapping of a bactericidal anti-GNA33 mAb using overlapping peptides shows that the mAb recognizes peptides from GNA33 and PorA that share a QTP sequence that is necessary but not sufficient for binding. By flow cytometry, mouse antisera prepared against rGNA33 and the anti-GNA33 mAb bind as well as an anti-PorA P1.2 mAb to the surface of eight of nine N. meningitidis serogroup B strains tested with the P1.2 serosubtype. Anti-GNA33 Abs also are bactericidal for most P1.2 strains and, for susceptible strains, the activity of an anti-GNA33 mAb is similar to that of an anticapsular mAb but less active than an anti-P1.2 mAb. Anti-GNA Abs also confer passive protection against bacteremia in infant rats challenged with P1.2 strains. Thus, GNA33 represents one of the most effective immunogenic mimetics yet described. These results demonstrate that molecular mimetics have potential as meningococcal vaccine candidates.
Granoff
D M
DM
Children's Hospital Oakland Research Institute, Oakland, CA 94609, USA. dgranoff@chori.org
Moe
G R
GR
Giuliani
M M
MM
Adu-Bobie
J
J
Santini
L
L
Brunelli
B
B
Piccinetti
F
F
Zuno-Mitchell
P
P
Lee
S S
SS
Neri
P
P
Bracci
L
L
Lozzi
L
L
Rappuoli
R
R
D000328:Adult; D000818:Animals; D000833:Animals, Suckling; D000907:Antibodies, Bacterial / Q000096:biosynthesis* / Q000627:therapeutic use; D000942:Antigens, Bacterial / Q000235:genetics / Q000276:immunology*; D001666:Binding Sites, Antibody; D001770:Blood Bactericidal Activity; D015153:Blotting, Western; D002462:Cell Membrane / Q000737:chemistry / Q000276:immunology / Q000382:microbiology; D005260:Female; D005434:Flow Cytometry; D019084:Fluorescent Antibody Technique, Indirect; D016680:Genome, Bacterial; D016695:Glycosyltransferases / Q000276:immunology; D006801:Humans; D008589:Meningococcal Infections / Q000276:immunology* / Q000517:prevention & control; D051379:Mice; D018716:Molecular Mimicry / Q000235:genetics / Q000276:immunology*; D009345:Neisseria meningitidis / Q000235:genetics / Q000276:immunology* / Q000378:metabolism; D010449:Peptide Mapping; D018272:Porins / Q000276:immunology; D051381:Rats; D011947:Receptors, Antigen, B-Cell / Q000378:metabolism
D000907:Antibodies, Bacterial; D000942:Antigens, Bacterial; D018272:Porins; D011947:Receptors, Antigen, B-Cell; C057699:porin protein, Neisseria; D016695:Glycosyltransferases; C085441:MltA protein, bacteria